Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Saturday, April 20, 2024 | Back issues
Courthouse News Service Courthouse News Service

Medical Merger

Shareholders claim in a federal class action that directors of The Medicines Company made false and misleading statements to support its sale to Novartis for $85 per share or $9.7 billion.

WILMINGTON, Del. — Shareholders claim in a federal class action that directors of The Medicines Company made false and misleading statements to support its sale to Novartis for $85 per share or $9.7 billion.

Categories / Business, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...